This site expansion will support faster enrolment in this cost-efficient, investigator-initiated study evaluating eftilagimod alpha (efti) in combination w...
The paper presents final analysis results from a multicenter, double-blind, phase 3, randomized controlled study (NCT05582629) evaluating the efficacy and ...
The RP2D of ivaltinostat (250 mg/m2) was determined by the Safety Review Committee (SRC) following a thorough safety data review from 3 cohorts of increasi...
"The NMPA approval of vebreltinib is an important milestone toward providing a new treatment option for patients with MET exon 14 skipping NSCLC in China. ...
SciSparc Ltd. (NASDAQ: SPRC), a specialty, clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central...
GBM AGILE Adaptive Platform Trial Recruiting in Australia Austin Health in Melbourne and Royal North Shore Hospital in Sydney are Now Enrolling Patients ...
Planning to initiate Phase 1/2 trial in pediatric DMD Patients – – First cohort to study patients 4 to < 6 years of age – &l...
Demonstrated improvements among best reported of fibrosis-reducing compounds - - Liver stiffness results complemented by positive changes in disease bioma...
Pueraria mirifica grows only in the rich soils of the high-altitude rainforests of Thailand and has been used by the Thais for a millennium as a rejuvenato...
BioPhy launched its AI operating system that radically accelerates the identification and development of the most promising drug candidates. By combi...
“The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, ...
-Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, an...
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia. Top-line results for on-going, 52-week...
– Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 202...
© 2025 Biopharma Boardroom. All Rights Reserved.
